Catalent today announced that it has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market, for $1 billion.
Catalent today announced the launch of OptiGel® DR technology for the formulation and manufacture of delayed/enteric release softgels. The technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step.
Catalent Pharma Solutions today announced that it is to participate in a half-day workshop, along with Euromonitor International, on the formulation of consumer health products, as part of SupplySide West.
Catalent Pharma Solutions today announced it has entered into an exclusive long-term supply agreement to produce the next generation of Pfizer Inc.’s leading over-the-counter (OTC) pain relief product with the launch of new Advil Liqui-Gels Minis.